NCT02697474View on ClinicalTrials.gov

Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

January 31, 2017

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Euvax B®: Hepatitis B vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Euvax B®: Hepatitis B vaccine

0.5 mL, Intramuscular

Trial Locations (2)

Unknown

Bangkok

Khon Kaen

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02697474 - Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. | Biotech Hunter | Biotech Hunter